Affiliation:
1. From the Harvard School of Public Health (B.R.R., A.K.H., G.L.R.), Harvard Medical School and Massachusetts General Hospital (G.L.R.), Boston.
Abstract
Background
—Because the increased fibrinolytic resistance of older thrombi may be caused by the continuous cross-linking action of fibrin-bound activated factor XIII (FXIIIa), we examined the persistence of FXIIIa catalytic activity in clots of various ages.
Methods and Results
—The time-related changes in FXIIIa activity in clots was measured with (1) α
2
-antiplasmin (α
2
AP), a physiological glutamine substrate; (2) α
2
AP
13–24
, a peptide; and (3) pentylamine, a nonspecific lysine substrate. The cross-linking of α
2
AP, α
2
AP
13–24
, and pentylamine into fibrin by clot-bound FXIIIa declined rapidly with half-lives of 19, 21, and 26 minutes, respectively. Mutational studies showed that glutamine 14 (but not glutamine 3 or 16) and valine 17 of α
2
AP
13–24
were required for efficient cross-linking to fibrin. The loss of activity was not due primarily to FXIIIa proteolysis and was partially restored by reducing agents, suggesting that oxidation contributes to the loss of the enzyme’s activity in clots. In vivo, the ability of thrombus-bound FXIIIa to cross-link an infused α
2
AP
13–24
peptide into existing pulmonary emboli also declined significantly over time.
Conclusions
—FXIIIa cross-links α
2
AP and an α
2
AP peptide, in a sequence-specific manner, into formed clots with a catalytic half-life of ≈20 minutes. This indicates that FXIIIa activity is a hallmark of new thrombi and that the antifibrinolytic cross-linking effects of FXIIIa are achieved more rapidly in thrombi than previously believed.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献